Core Viewpoint - Shanghai Heyu Biopharmaceutical Technology Co., Ltd. announced that its self-developed oral and highly selective small molecule CSF-1R inhibitor, Beijiemai (pimitinib hydrochloride capsules), has received formal acceptance of its New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for the systemic treatment of patients with tenosynovial giant cell tumors (TGCT) [1][2]. Group 1 - Beijiemai is a novel, oral, highly selective, and efficient small molecule CSF-1R inhibitor developed independently by the company [3]. - The NDA acceptance is based on positive results from the global multicenter, randomized, double-blind, placebo-controlled Phase III MANEUVER study, which showed a significant improvement in objective response rate (ORR) for TGCT patients treated with Beijiemai compared to the placebo group [2]. - All secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reduced stiffness and pain [2]. Group 2 - TGCT is a rare locally aggressive tumor that occurs in or around joints, leading to swelling, stiffness, and restricted movement, significantly impacting patients' daily activities and quality of life [2]. - Beijiemai has already been approved by the National Medical Products Administration (NMPA) in China for symptomatic TGCT adult patients who may experience functional limitations or severe complications from surgical resection [3]. - The company has reached an agreement with Merck for the global commercialization rights of Beijiemai, which has also received breakthrough therapy designation (BTD) from the FDA and priority medicine (PRIME) designation from the European Medicines Agency (EMA) [3].

Core Viewpoint - The new drug application (NDA) for the oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijiemai® (pimitinib hydrochloride capsules), developed by He Yu Pharmaceutical, has been officially accepted by the FDA for the systemic treatment of patients with tenosynovial giant cell tumor (TGCT) [1][2] Group 1: Drug Development and Approval - Beijiemai® has been developed by He Yu Pharmaceutical and is licensed to Merck for global commercialization [1] - The drug received approval from the National Medical Products Administration (NMPA) in China in December 2025 for symptomatic TGCT adult patients who may experience functional limitations or severe complications from surgical resection [1] - The NDA acceptance by the FDA is based on positive results from the global multicenter, randomized, double-blind, placebo-controlled Phase III MANEUVER study [2] Group 2: Clinical Study Results - The study demonstrated that patients with TGCT treated with Beijiemai® showed a significantly higher objective response rate (ORR) at week 25 compared to the placebo group, as assessed by the blinded independent review committee (BIRC) using RECIST v1.1 criteria [2] - All secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reductions in stiffness and pain [2] - Long-term data with a median follow-up of 14.3 months indicated a continuous improvement in ORR for patients who received Beijiemai® treatment from the start of the study [2] Group 3: Disease Context and Market Potential - TGCT is a rare locally aggressive tumor that occurs in or around joints, leading to swelling, stiffness, and restricted movement, significantly impacting patients' daily activities and quality of life [2] - If not treated promptly or if recurrence occurs, TGCT can cause irreversible damage to bones, joints, and surrounding tissues [2] - With the ongoing submissions and future approvals in major global markets, Beijiemai® is expected to provide an innovative treatment option that is effective, well-tolerated, and administered once daily, addressing the unmet clinical needs in this disease area [2]

Core Viewpoint - The new drug application (NDA) for the oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijiemai® (pimitinib hydrochloride capsules), developed by He Yu Pharmaceutical, has been officially accepted by the FDA for the systemic treatment of patients with tenosynovial giant cell tumor (TGCT) [1][2] Group 1: Drug Development and Approval - Beijiemai® was developed independently by He Yu Pharmaceutical and is licensed to Merck for global commercialization [1] - The drug received approval from the National Medical Products Administration (NMPA) in China in December 2025 for symptomatic TGCT adult patients who may experience functional limitations or severe complications from surgical resection [1] - The NDA acceptance by the FDA is based on positive results from the global multicenter, randomized, double-blind, placebo-controlled Phase III MANEUVER study [2] Group 2: Clinical Study Results - The study demonstrated that patients with TGCT treated with Beijiemai® showed a significantly higher objective response rate (ORR) compared to the placebo group at week 25, as assessed by a blinded independent review committee (BIRC) using RECIST v1.1 criteria [2] - All secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reductions in stiffness and pain [2] - Long-term data from a median follow-up of 14.3 months indicated a continuous increase in ORR for patients who received Beijiemai® treatment from the start of the study [2] Group 3: Disease Context and Market Potential - TGCT is a rare locally aggressive tumor that occurs in or around joints, leading to swelling, stiffness, and restricted movement, significantly impacting patients' daily activities and quality of life [2] - If untreated or recurrent, TGCT can cause irreversible damage to bones, joints, and surrounding tissues [2] - With the ongoing submissions and future approvals in major global markets, Beijiemai® is expected to provide an innovative treatment option that is effective, well-tolerated, and administered once daily, addressing the unmet clinical needs in this disease area [2]

Core Viewpoint - The National Medical Products Administration (NMPA) has approved Bejimai (pimitidine hydrochloride capsules) for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adult patients, marking it as the first innovative drug approved for TGCT treatment in China [1][4]. Group 1: Drug Approval and Significance - Bejimai is a colony-stimulating factor-1 receptor inhibitor, providing a new treatment option for TGCT, a rare locally aggressive tumor that can lead to significant joint swelling, stiffness, and functional limitations [1][4]. - The approval is based on the positive results from the global Phase III MANEUVER study, which were presented at the 2025 American Society of Clinical Oncology Annual Meeting [4]. Group 2: Clinical Impact and Patient Needs - Many TGCT patients in China face treatment challenges, as there are limited options beyond surgery, particularly for those with tumor recurrence or inoperable cases [4]. - The approval of Bejimai offers clinicians the opportunity to provide an effective and well-tolerated systemic treatment option, representing progress in the management of this difficult-to-treat disease [4]. - The pain and activity limitations caused by TGCT significantly impact patients' daily lives, leading to considerable mental stress, highlighting the importance of effective treatment options like Bejimai [4].